You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Vaccines
Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis
Login
Username:

Password:


Related Headlines

BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU

Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s

ExpreS2ion Biotech signs definitive licensing deal with Serum Institute of India for novel malaria vaccines

PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt

Lunai Bioworks publishes breakthrough on second-generation allogeneic dendritic cell therapy in vaccines

Frontier IP portfolio company achieves breakthrough in livestock vaccine trials

GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine

Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses

Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats

4basebio synthetic DNA used in Phase I/II mRNA therapy trial

Arcturus reports interim Phase 2 data for ARCT-032 in cystic fibrosis

Sanofi reports data showing high-dose flu vaccine delivers superior protection for older adults

GC Biopharma granted CMO rights for Curevo Vaccine's shingles vaccine

TransCode acquires Polynoma and secures USD25m investment from CK Life Sciences

Wasatch BioLabs adds three Oxford Nanopore-developed research-use-only assays to service portfolio

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025